| Management target | Revenue 10.0% FY26 |
|---|
| Margins | Blueberry commands 6x strawberry price; shifting to premium 18-25mm grades. |
|---|---|
| Order book | ₹50.11 Cr across 20 orders; NAFED largest contract (₹12.95 Cr). |
| Demand visibility | Strong; 10x growth in imports since 2020. |
| Management confidence | High; leveraging 30+ years of tissue culture DNA. |
Growth
Projected FY26 revenue exceeds ₹110 Cr, up from ₹100 Cr+ in 2024. Indian blueberry demand is growing at 18% CAGR.
Outlook
Expanding blueberry commercial footprint; current order inflow of ₹50.11 Cr across 20 contracts for FY26.
Risks
High-capital intensive greenhouse setup and dependence on specific climate zones for blueberry varieties.
Earnings Call filed with NSE, NSE: SHEEL. Summary written with AI assistance from the document.
Sheel Biotech Ltd: key numbers
- Share price
- ₹63.30
- Market cap
- ₹128.8 Cr
- Revenue (annual)
- ₹110.0 Cr
- Net profit (annual)
- ₹11.76 Cr
- P/E (TTM)
- 11.0×Sector 41.4×
- Promoter holding
- 72.29%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sheel Biotech Ltd
All →Sheel Biotech Legal & Regulatory
SEBI issued an advisory letter to Sheel Biotech Limited for delayed disclosure of a monitoring agency report. No monetary penalty or restrictions were imposed on the company.
Sheel Biotech Annual General Meeting
Sheel Biotech Limited held its 35th Annual General Meeting on September 24, 2026. The meeting covered adoption of financial statements and approval of other ordinary resolutions.
Sheel Biotech Other Announcement
Sheel Biotech intimated that its Statutory Auditor Shyam Sunder Mangla & Co LLP has changed its name to S S Mangla & Co LLP effective 18 December 2025. No change in the auditor appointment itself.
Sheel Biotech Bags ₹14.53 Cr Order
Sheel Biotech Limited has finalised a commercial transaction for its Blueberry project, valued at ₹14.53 Crore. This contract marks a significant business development for the company.
- Value
- ₹14.53 Cr
Sheel Biotech Annual General Meeting
Sheel Biotech Limited scheduled its 35th Annual General Meeting for September 24, 2026. The company also announced the record date and book closure period.
Sheel Biotech H2 FY26 Results: Net Profit ₹11.6 Cr, Down 20.0% YoY
Sheel Biotech Ltd reported revenue from operations of ₹88.2 Cr (-2.5% YoY) and net profit of ₹11.6 Cr (-20.0% YoY) for H2 FY26.
- Key figure
- Net profit ₹11.6 Cr · -20.0% YoY